FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after ≥2 prior therapies. In pooled phase I/II data, ...

A Penn Medicine study has shown that tailoring chemotherapy doses based on genetic testing can significantly improve safety for gastrointestinal (GI) cancer patients. Screening for variants in two key ...